Core Principles and Other Requirements for Swap Execution Facilities; Correction, 47154 [2013-18773]
Download as PDF
<![CDATA[
47154
Federal Register / Vol. 78, No. 150 / Monday, August 5, 2013 / Rules and Regulations
(b) Determination of claims—(1)
Delegation of authority to determine
claims. The General Counsel, and such
employees of the Legal Division as the
General Counsel may designate are
authorized to consider, ascertain, adjust,
determine, compromise, and settle
claims pursuant to the FTCA, as
amended, and the regulations contained
in 28 CFR part 14 and in this section.
(2) Disallowance of claims. If the
General Counsel, or the General
Counsel’s designee, denies a claim, the
General Counsel or designee shall notify
the claimant, or the claimant’s duly
authorized agent or legal representative.
Dated: July 11, 2013.
Richard Cordray,
Director, Bureau of Consumer Financial
Protection.
(b) For transactions cleared by a
derivatives clearing organization:
(1) By ensuring that the swap
execution facility has the capacity to
route transactions to the derivatives
clearing organization in a manner
acceptable to the derivatives clearing
organization for purposes of clearing;
and
(2) By coordinating with each
derivatives clearing organization to
which it submits transactions for
clearing, in the development of rules
and procedures to facilitate prompt and
efficient transaction processing in
accordance with the requirements of
§ 39.12(b)(7) of this chapter.
Appendix B to Part 37—Guidance on,
and Acceptable Practices in,
Compliance With Core Principles
[Corrected]
2. On page 33600, in the second
column, under the heading Core
Principle 3 of Section 5h of the Act—
Swaps Not Readily Susceptible to
Manipulation, in paragraph (a)(3),
correct the reference to ‘‘section c(5)’’ to
read ‘‘section c(4).’’
[FR Doc. 2013–18844 Filed 8–2–13; 8:45 am]
BILLING CODE 4810–AM–P
COMMODITY FUTURES TRADING
COMMISSION
17 CFR Part 37
RIN 3038–AD18
Dated: July 31, 2013.
Christopher J. Kirkpatrick,
Deputy Secretary of the Commission.
Core Principles and Other
Requirements for Swap Execution
Facilities; Correction
[FR Doc. 2013–18773 Filed 8–2–13; 8:45 am]
BILLING CODE 6351–01–P
Commodity Futures Trading
Commission.
ACTION: Final rule; correction.
AGENCY:
The Commodity Futures
Trading Commission is correcting a
final rule that appeared in the Federal
Register of June 4, 2013 (78 FR 33476).
The final rule applies to the registration
and operation of a new type of regulated
entity named a swap execution facility,
and implements provisions of the DoddFrank Wall Street Reform and Consumer
Protection Act.
DATES: The effective date of this
correction is August 5, 2013.
FOR FURTHER INFORMATION CONTACT:
Amir Zaidi, Special Counsel, Division of
Market Oversight, Commodity Futures
Trading Commission, Three Lafayette
Center, 1155 21st Street NW.,
Washington, DC 20581; 202–418–6770;
azaidi@cftc.gov.
SUPPLEMENTARY INFORMATION: In FR Doc.
2013–12242 appearing on page 33476 in
the Federal Register of Tuesday, June 4,
2013, the following corrections are
made:
mstockstill on DSK4VPTVN1PROD with RULES
SUMMARY:
§ 37.702
[Corrected]
1. On page 33591, in the second
column, in § 37.702 General financial
integrity, paragraph (b) is corrected to
read as follows:
VerDate Mar<15>2010
16:48 Aug 02, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 101
[Docket No. FDA–2005–N–0404]
RIN 0910–AG84
Food Labeling; Gluten-Free Labeling of
Foods
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA or we) is issuing a
final rule to define the term ‘‘glutenfree’’ for voluntary use in the labeling of
foods. The final rule defines the term
‘‘gluten-free’’ to mean that the food
bearing the claim does not contain an
ingredient that is a gluten-containing
grain (e.g., spelt wheat); an ingredient
that is derived from a gluten-containing
grain and that has not been processed to
remove gluten (e.g., wheat flour); or an
ingredient that is derived from a glutencontaining grain and that has been
processed to remove gluten (e.g., wheat
starch), if the use of that ingredient
SUMMARY:
PO 00000
Frm 00002
Fmt 4700
Sfmt 4700
results in the presence of 20 parts per
million (ppm) or more gluten in the
food (i.e., 20 milligrams (mg) or more
gluten per kilogram (kg) of food); or
inherently does not contain gluten; and
that any unavoidable presence of gluten
in the food is below 20 ppm gluten (i.e.,
below 20 mg gluten per kg of food). A
food that bears the claim ‘‘no gluten,’’
‘‘free of gluten,’’ or ‘‘without gluten’’ in
its labeling and fails to meet the
requirements for a ‘‘gluten-free’’ claim
will be deemed to be misbranded. In
addition, a food whose labeling includes
the term ‘‘wheat’’ in the ingredient list
or in a separate ‘‘Contains wheat’’
statement as required by a section of the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act) and also bears the claim
‘‘gluten-free’’ will be deemed to be
misbranded unless its labeling also
bears additional language clarifying that
the wheat has been processed to allow
the food to meet FDA requirements for
a ‘‘gluten-free’’ claim. Establishing a
definition of the term ‘‘gluten-free’’ and
uniform conditions for its use in food
labeling will help ensure that
individuals with celiac disease are not
misled and are provided with truthful
and accurate information with respect to
foods so labeled. We are issuing the
final rule under the Food Allergen
Labeling and Consumer Protection Act
of 2004 (FALCPA).
DATES: Effective date: The final rule
becomes effective on September 4, 2013.
Compliance date: The compliance date
of this final rule is August 5, 2014. See
section II.B.4 (comment 35 and response
35) for an additional explanation of the
compliance date and implementation of
this final rule.
FOR FURTHER INFORMATION CONTACT:
Felicia B. Billingslea, Center for Food
Safety and Applied Nutrition (HFS–
820), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740, 240–402–2371, FAX: 301–
436–2636, email: GlutenFreeFinalRule
Questions@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Executive Summary
Purpose of the Rule
Need for the rule: Celiac disease is a
hereditary, chronic inflammatory
disorder of the small intestine triggered
by the ingestion of certain storage
proteins referred to as gluten occurring
in wheat, rye, barley, and crossbreeds of
these grains. Celiac disease has no cure,
but individuals who have this disease
are advised to avoid all sources of
gluten in their diet to protect against
adverse health effects associated with
the disease. Many manufacturers
currently label their food with a
E:\FR\FM\05AUR1.SGM
05AUR1
]]>Agencies
[Federal Register Volume 78, Number 150 (Monday, August 5, 2013)]
[Rules and Regulations]
[Page 47154]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-18773]
=======================================================================
-----------------------------------------------------------------------
COMMODITY FUTURES TRADING COMMISSION
17 CFR Part 37
RIN 3038-AD18
Core Principles and Other Requirements for Swap Execution
Facilities; Correction
AGENCY: Commodity Futures Trading Commission.
ACTION: Final rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Commodity Futures Trading Commission is correcting a final
rule that appeared in the Federal Register of June 4, 2013 (78 FR
33476). The final rule applies to the registration and operation of a
new type of regulated entity named a swap execution facility, and
implements provisions of the Dodd-Frank Wall Street Reform and Consumer
Protection Act.
DATES: The effective date of this correction is August 5, 2013.
FOR FURTHER INFORMATION CONTACT: Amir Zaidi, Special Counsel, Division
of Market Oversight, Commodity Futures Trading Commission, Three
Lafayette Center, 1155 21st Street NW., Washington, DC 20581; 202-418-
6770; azaidi@cftc.gov.
SUPPLEMENTARY INFORMATION: In FR Doc. 2013-12242 appearing on page
33476 in the Federal Register of Tuesday, June 4, 2013, the following
corrections are made:
Sec. 37.702 [Corrected]
1. On page 33591, in the second column, in Sec. 37.702 General
financial integrity, paragraph (b) is corrected to read as follows:
(b) For transactions cleared by a derivatives clearing
organization:
(1) By ensuring that the swap execution facility has the capacity
to route transactions to the derivatives clearing organization in a
manner acceptable to the derivatives clearing organization for purposes
of clearing; and
(2) By coordinating with each derivatives clearing organization to
which it submits transactions for clearing, in the development of rules
and procedures to facilitate prompt and efficient transaction
processing in accordance with the requirements of Sec. 39.12(b)(7) of
this chapter.
Appendix B to Part 37--Guidance on, and Acceptable Practices in,
Compliance With Core Principles [Corrected]
2. On page 33600, in the second column, under the heading Core
Principle 3 of Section 5h of the Act--Swaps Not Readily Susceptible to
Manipulation, in paragraph (a)(3), correct the reference to ``section
c(5)'' to read ``section c(4).''
Dated: July 31, 2013.
Christopher J. Kirkpatrick,
Deputy Secretary of the Commission.
[FR Doc. 2013-18773 Filed 8-2-13; 8:45 am]
BILLING CODE 6351-01-P
